SLDB

Solid BiosciencesB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-22

Current thesis

The best case is that SGT-003 keeps showing differentiated tolerability and biomarker/functional support, Phase 3 dosing starts on time, and FDA discussions make an accelerated route look viable; combined with runway into H1 2028, that can support a sharper rerating from a depressed base.

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +0.4.

What can break

Competitive pressure from Sarepta, REGENXBIO, and other Duchenne programs could compress SLDB’s differentiation narrative.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $8.60 · Bull $11.50 · Bear $5.50

Data freshness

Prices

As of 2026-07-22

Fundamentals

As of 2026-07-21 • Vendor: Data Vendor v1

Scores

As of 2026-07-22 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-17 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-22

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net Neutral

Target $17.50

Why

Momentum91 · Δ7d +0.4

Value41 · Δ7d -0.0

Sentiment52 · Δ7d +11.7

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

+0.4

Δ21d

+5.1

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.0

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+11.7

Δ21d

+13.5

Why this grade

Composite grade B. Momentum 90.6 / Value 41.1 / Sentiment 52.2

Fundamentals (TTM)

As of 2026-07-21

Market Cap

$832.88M

Beta

2.68

Shares Out

98.45M

P/E (TTM) · Derived

-4.2

P/S (TTM)

P/FCF (TTM) · Derived

-4.81

Rev YoY

-100.0%

EPS YoY

-12.7%

Gross Margin

+55.0%

Op Margin

Net Debt

-$167.91M

Current Ratio

13.10

As of 2026-07-22 • Updated nightlySource: Internal modelMethodology